World's Best Scientists 2026 revealed!
Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
163
Citations
96788
World Ranking
688
National Ranking
15

Jean-Yves Blay publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Yves Blay sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,361 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jean-Yves Blay D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Yves Blay sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 163 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Jean-Yves Blay is affiliated with Claude Bernard University Lyon 1 in France and has a substantial body of research focused on medicine, with a special emphasis on pulmonary and respiratory medicine, oncology, rheumatology, gastroenterology, and molecular biology.

The scientist's work covers several main topics, including:

  • Sarcoma Diagnosis and Treatment
  • Gastrointestinal Tumor Research and Treatment
  • Vascular Tumors and Angiosarcomas
  • Cardiac Tumors and Thrombi
  • Cancer Genomics and Diagnostics
  • Gastric Cancer Management and Outcomes
  • Bone Tumor Diagnosis and Treatments

Jean-Yves Blay has co-authored extensively with several frequent collaborators, including:

  • Antoîne Italiano
  • Nicolas Penel
  • Armelle Dufresne
  • Mehdi Brahmi
  • François Bertucci

The scientist has published numerous papers in prominent journals. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • European Journal of Cancer
  • Cancers

Among the recent papers authored or co-authored by Jean-Yves Blay are:

  • "Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2021, Annals of Oncology)
  • "Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2021, Annals of Oncology)
  • "The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients" (2020, European Journal of Cancer)
  • "Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial" (2020, The Lancet Oncology)
  • "Gastrointestinal stromal tumours" (2021, Nature Reviews Disease Primers)

Best Publications

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

    Carola H. Ries;Michael A. Cannarile;Sabine Hoves;Jörg Benz

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

    Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini

  • Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

    Michael Gobert;Isabelle Treilleux;Nathalie Bendriss-Vermare;Thomas Bachelot

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

    David Thomas;Robert Henshaw;Keith M Skubitz;Sant Chawla

  • Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor

    C. Menetrier-Caux;G. Montmain;G. Montmain;M.C. Dieu;M.C. Dieu;C. Bain;C. Bain

  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

    Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO (vol 16, pg 566, 2005)

    JY Blay;S Bonvalot;P Casali;H Choi

Frequent Co-Authors

Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Antoine Italiano
Antoine Italiano University of Bordeaux
Christine Chevreau
Christine Chevreau DuPont (United States)
Paolo G. Casali
Paolo G. Casali University of Milan
François Bertucci
François Bertucci Aix-Marseille University
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Alessandro Gronchi
Alessandro Gronchi University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a medical career in the USA continues to diversify, offering students flexible options online. Those interested in a career shift to nursing, but who do not already hold a nursing license, may consider direct entry msn programs for non-nurses online. These accelerated programs allow students from various backgrounds to earn a master's degree and qualify for nursing practice, often at a faster pace than traditional routes.

Applicants looking for more accessible entry points into nursing may be interested in nursing schools with high acceptance rates. These institutions are ideal for those wanting to overcome common admission barriers. Additionally, prospective nurses who wish to avoid standardized testing can find absn programs that don't require teas, making the path to nursing school even more approachable.

For individuals interested in healthcare but not direct patient care, administrative roles are also in demand. There are reputable medical coding and billing classes online with financial aid, letting students enter this growing field with flexible, affordable study options.

Best Scientists Citing Jean-Yves Blay

Trending Scientists

Recently Published Articles